Business Context and Reporting Period
This Form 8-K, dated July 2, 2004, reports a fundamental corporate transformation for the registrant, formerly known as Used Kar Parts, Inc. The company completed the acquisition of Xenomics, a California corporation, and simultaneously changed its corporate name to Xenomics, Inc. The reporting period covers events finalized on July 2, 2004, with a 111-for-1 stock split scheduled to become effective under Florida law on July 26, 2004. The company intends to pivot its operations to develop diagnostic tests utilizing transrenal nucleic acids for prenatal diagnosis, cancer detection, and transplantation compatibility.
Key Financial Metrics and Capital Structure
- Capital Raised: The company completed a private placement of 2,645,210 shares of common stock, generating aggregate proceeds of $2,512,949.50 from 17 accredited investors.
- Share Redemption: The company redeemed 1,971,734 pre-split shares (equivalent to 218,862,474 post-split shares) from principal shareholder Panetta Partners Ltd. for $500,000 ($0.0023 per share).
- Acquisition Consideration: The acquisition of Xenomics was funded by issuing 2,258,001 shares of common stock to Xenomics' five shareholders.
- Outstanding Shares: Following these transactions, the company has 15,588,737 shares outstanding.
- Stock Options: The company adopted a 2004 Stock Option Plan and issued options to acquire 3,750,000 shares to officers and consultants at an exercise price of $1.25 per share.
- Financial Statements: The filing explicitly states that financial statements and pro forma financial information are not included in this report and will be filed by amendment within 60 days.
Material Changes Versus Prior Period
The filing represents a complete change in the company's business identity and asset base. The registrant transitioned from "Used Kar Parts, Inc." to "Xenomics, Inc." through a reverse merger or acquisition structure. Key material changes include:
- Corporate Name: Changed from Used Kar Parts, Inc. to Xenomics, Inc.
- Capital Structure: Implementation of a 111-for-1 stock split and significant dilution through the issuance of shares for the acquisition and private placement.
- Management and Board: New directors appointed include L. David Tomei (Chairman), Samuil Umansky, Gary Jacobs, and Donald Picker. Samuil Umansky was appointed President and Chief Scientific Officer.
- Business Focus: Shifted from automotive parts to biotechnology and diagnostic testing.
Guidance, Risks, and Contingencies
The filing outlines specific contingencies and risks associated with the acquisition and future financing:
- Technology Acquisition Contingency: A Technology Acquisition Agreement grants former Xenomics shareholders an option to reacquire Xenomics technology if the company fails to apply at least 50% of all financing raised to the development of Xenomics technology by July 1, 2006. If exercised, this would result in the former shareholders acquiring all shares and share equivalents held by the company.
- Regulatory Compliance: The private placement was conducted under Rule 506 of Regulation D, exempt from registration, with no general solicitation or broker involvement.
- Future Filings: Investors should note that audited financial statements and pro forma data are not yet available and are pending a future amendment.
Key Facts for Investor Verification
- Verify the effective date and mechanics of the 111-for-1 stock split scheduled for July 26, 2004.
- Confirm the status of the pending amendment containing financial statements and pro forma information due within 60 days of this filing.
- Monitor the company's financing activities to ensure compliance with the 50% funding threshold required to prevent the former Xenomics shareholders from exercising their technology reacquisition option.
- Review the Voting Agreement and employment contracts filed as exhibits to understand the control dynamics between the new investors, former Xenomics shareholders, and original shareholders.
- Validate the cash position of $2.5 million raised against the company's immediate burn rate for biotechnology development.